Voisard Asset Management Group, Inc. Viridian Therapeutics, Inc.\De Transaction History
Voisard Asset Management Group, Inc.
- $240 Billion
- Q3 2024
A detailed history of Voisard Asset Management Group, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Voisard Asset Management Group, Inc. holds 100 shares of VRDN stock, worth $1,979. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$1,979
Previous $1.3 Million
74.87%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VRDN
# of Institutions
179Shares Held
76.8MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$94.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$87.5 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$76.8 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$74.2 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$68.2 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $789M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...